Corcept Therapeutics Incorporated (CORT) Stock Score, Valuation & Financial Research
Corcept Therapeutics Incorporated is in the Healthcare sector and Medical - Pharmaceuticals industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for CORT
Corcept Therapeutics Incorporated currently has a Wall Street Score of 35/100. The stored market price is $111.81. Its financial score is 36/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Corcept Therapeutics Incorporated does
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clin
CORT financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $111.81
- Market capitalization:
- $12.09B
- Revenue:
- $830.8M
- Net income:
- $54.9M
- Free cash flow:
- $141.8M
- Cash:
- $111.0M
- Total debt:
- $9.4M
- EPS:
- 0.52
- P/E ratio:
- 215.0x
- Financial score:
- 36/100
- Valuation score:
- 0/100
- Revenue score:
- 33/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $141.8M, showing positive cash generation.
- The balance sheet shows $111.0M of cash versus $9.4M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CORT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.